Biocartis « Terug naar discussie overzicht

Biocartis forum geopend

6.454 Posts, Pagina: « 1 2 3 4 5 6 ... 179 180 181 182 183 184 185 186 187 188 189 ... 319 320 321 322 323 » | Laatste

Omlaag ↓

StiMO 29 oktober 2020 20:41

Koopt iedereen morgen gewoon terug.
Er zal wel nieuwe samenwerking komen

DRTVR 29 oktober 2020 21:18

quote:
ulyss schreef op 29 oktober 2020 19:43:
Beste,

ik wens een klacht in te dienen tegen Biocartis ten gevolge van achterhouden informatie en lekken van informatie naar beperkt publiek.

Daarom dien ik klacht in tegen achterhouden informatie, lekken van informatie en wens ik xxxx schadevergoeding voor de gelede schade
Dank je wel om mijn klacht in overweging te nemen
Met vriendelijke groeten

Gaan we doen, alvast bedankt.

DRTVR 29 oktober 2020 21:29

Klacht verstuurd, heb gewoon mijn aandelen terug gevraagd :)

Poelifinario 29 oktober 2020 22:24

Je wil geen zaken doen met exact sciences. Vraag dat maar aan MDX health en zijn toenmalige CEO.

Flatlander 29 oktober 2020 23:57

I had to leave the office this morning after my earlier posts. I get back and I see BCART has offered some additional information which seemed to obviously be missing this morning (i.e., information on the $12 million in liquidated damages). I suspect the asset returned to BCART was a license to use the idylla platform. The press releases still smack of being very disingenuous! Breast cancer and the need for treatment may be pushed into the future but COVID will definitely not destroy the market. Coming out of the pandemic there will be tremendous pent up demand and more than likely some lab capacity will be tied up with COVID testing. This makes it an ideal time to try to position the POC IVD test like OncoType Dx. I go back to my earlier hypothesis. EXACT is banking on their new precision oncology business and looking to launch labs in foreign markets. The labs are undoubtedly key to their high sensitivity liquid biopsy testing (so they would need the lab regardless of Oncotype DX breast is launched POC or as a conventional lab test). This liquid biopsy test put a huge dent in the Illumina-Grail merger valuation about a month ago.

The PR also makes no mention of the OncoType Dx prostate test. The prostate collaboration was announced on Dec 4, 2018 (again without much market reaction). How could a PR be released about the termination of the partnership collaboration without mentioning the other product line for which milestone payments have already been paid out?

The volume today was 10X higher so it shook out a lot of shareholders with really sketchy misleading information. In the U.S., the class action lawyers would be circling. That doesn't happen in Belgium? Someone asked a few pages ago whether I viewed the sell off as a buying opportunity? I sold about a quarter of my position a week or so ago to balance Novacyt gains, but I'm still long a sizeable position. As I posted in early September, I thought the COVID excuse for shelving OncoType DX Breast collaboration was likely misleading. I held onto shares since I believe that POC Oncology MDx
and Septicyte should find healthy markets when the products are fully registered. I'm not currently buying more shares for two reasons 1) the US tax loss rules require a 30 day waiting period between selling for a tax loss and buying new shares; and 2) the company needs to restore creditability. They should start by disclosing the status of Oncocyte DX prostate. Todays disclosure states that the collaboration termination will have no impact on potential growth in the US. The OncotypeDx prostate test was targeted at US Urology practices. Does that part of the collaboration survive? Worst PR imaginable!

FL

[verwijderd] 30 oktober 2020 00:32

Beside the great technology Biocartis has...

Can I agree with you Flatlander that knowned inside information on 28/10 was not shared to public, but only some inside partners? Causing a big drop of 10% on 28/10

That press release on 29/10 before opening markets was with hidden information, while US was sleeping, as you. Biocartis knew about the deal of 12M€. Understanding better the drop of 28/10

And when FSMA blocked the stock, waiting for a press release, suddenly the full information was shared

So , it"s not a question of good product, its a question of cheating to small share holders

What is your opinion please?

Some of us take action based on that information shared by the company, like me

Flatlander 30 oktober 2020 03:09

Ulyss

Not sure I totally agree. I'm in Chicago area but I got up early enough to see the 1st PR and down nearly 20%. To late to sell in my mind since it was already at the March lows. The PR statement struck me as extremely poorly thought out and conveyed to the public. My 1st post of the day was that surely their was some type of liquidated damages clause that would provide BCART with compensation for the agreement cancellation. Yes, I think that was negligent not to mention that consideration in the 1st PR. Whether, anyone can document that BCART provided a inside information to a "select few investors" on Oct 28 is a tough thing to prove. The bar for litigation is much lower in the States, I think they would have drawn droves of attorneys with the poorly worded PR and the down 20%.

I'm wondering who was buying today? One of the things I originally liked about BCART was that the shareholder base was widely disseminated (no one entity or even small group of investors could control outcomes). Since less than 800,000 shares changed hands, it can't have change much.

Regards
FL

Flatlander 30 oktober 2020 04:56

Ulyss

I think you may need to tone down the allegation that BCART shared inside information on 10/28. EXACT earnings on 10/27 included an impairment charge for the termination of the Idylla IVD. Here is the footnote:

"(4) During the third quarter of 2020, the Company began discussions with Biocartis regarding the termination of its agreements related to the development of an in vitro diagnostic version of the Oncotype DX Breast Recurrence Score test. As a result, and in connection with the preparation of the financial statements, the Company recorded a non-cash, pre-tax impairment loss of $200.0 million related to the in-process research and development intangible asset that was initially recorded as part of the combination with Genomic Health."

The bullet points also read:

"Intangible asset impairment of $209.7 million was primarily related to a one-time impairment of certain in-process research and development assets related to an in vitro diagnostic version of Oncotype DX"

investor.exactsciences.com/investor-r...

FL

Flatlander 30 oktober 2020 05:00

I don't see anything on the EXAS PR that says the prostate relationship has been cancelled.

FL

[verwijderd] 30 oktober 2020 07:50

quote:
Flatlander schreef op 30 oktober 2020 04:56:
Ulyss

I think you may need to tone down the allegation that BCART shared inside information on 10/28. EXACT earnings on 10/27 included an impairment charge for the termination of the Idylla IVD. Here is the footnote:

"(4) During the third quarter of 2020, the Company began discussions with Biocartis regarding the termination of its agreements related to the development of an in vitro diagnostic version of the Oncotype DX Breast Recurrence Score test. As a result, and in connection with the preparation of the financial statements, the Company recorded a non-cash, pre-tax impairment loss of $200.0 million related to the in-process research and development intangible asset that was initially recorded as part of the combination with Genomic Health."

The bullet points also read:

"Intangible asset impairment of $209.7 million was primarily related to a one-time impairment of certain in-process research and development assets related to an in vitro diagnostic version of Oncotype DX"

investor.exactsciences.com/investor-r...

FL

on 26 and 27/10 nothing special
on 28/10 big decrease
on 29/10 before opening, PR

So some had already the information on 28/10

DRTVR 30 oktober 2020 08:02

Ik heb er nog vertrouwen in, ga der terug in.

Floris de boskaboter 30 oktober 2020 08:15

@DRTVR: meteen instappen of even de eerste piek en mogelijk verdere drop afwachten?

DRTVR 30 oktober 2020 08:25

quote:
Floris de boskaboter schreef op 30 oktober 2020 08:15:
@DRTVR: meteen instappen of even de eerste piek en mogelijk verdere drop afwachten?

Hey, ben zeker niet zo thuis in de materie als sommigen hier, maar is er een reden dat het verder naar beneden zou tuimelen, zoals hier beweerd wordt was dat er de laatste 2 dagen gehandeld is met voorkennis, dus als dat de reden was is er verder geen nieuws geweest dat een verdere daling zou rechtvaardigen, maar nog es, laat u niet alleen leiden door mij.

Bonzai1 30 oktober 2020 08:51

quote:
Floris de boskaboter schreef op 30 oktober 2020 08:15:
@DRTVR: meteen instappen of even de eerste piek en mogelijk verdere drop afwachten?

Het lijkt me dat je jezelf die vraag vanochtend niet meteen zult moeten stellen. Als ik het goed zie, dan is het aandeel 'suspended' op Euronext. Maw: de handel is stilgezet, meer dan waarschijnlijk met het oogpunt op meer broodnodige duiding bij de communicaties van gisteren en de gevolgen voor de koers en het bedrijf. Ik verwacht maw dat de handel pas hernomen zal worden na een uitvoerig persbericht van/over Biocartis ... hopelijk niet over het feit dat er met voorkennis gecommuniceerd en gehandeld is geweest de laatste twee dagen. Dat zou mogelijk het bedrijf en de koers meer schaden en daar zit ikzelf persoonlijk niet op te wachten. Voor zij die hun stukken in paniek verkocht hebben, begrijp ik uiteraard dat zij het anders zien en verwachten ... time will tell :-)

CGCDLR 30 oktober 2020 08:54

Misschien hebben ze nog iets"vergeten" te communiceren.

Bonzai1 30 oktober 2020 08:55

Mocht de verduidelijking een verlengde worden van de boodschap van de CEO gisteren (het PB in de late namiddag), dan verwacht ik alvast dat de koers bij hervatting stevig de hoogte zal ingaan ....

Wilfro 30 oktober 2020 08:56

Ik zag in het nieuws op Binck net passeren dat de FSMA de handel in Biocartis terug heeft vrijgegeven, die zal dus hervatten om 9u bij het openen van euronext Brussel.

Over voorkennis gesproken, op de website van de FSMA vinden ze het niet nodig om dat ook daar even gelijktijdig te delen.

Bonzai1 30 oktober 2020 09:06

Klopt, handel gaat gewoon door ... des te beter, wat mij betreft. Ik onthoud het positieve uit de rechtzetting van de CEO gisteren (beperkte invloed op onze activiteiten en op onze vooruitzichten voor het komende jaar).

Floris de boskaboter 30 oktober 2020 09:07

Toch een klein pakketje bijgekocht aan 3,50. Na alle hektiek van gisteren denk/hoop ik toch de bodem voor even gezien te hebben? Kijk alvast uit naar verdere verduidelijking vanuit Biocartis vandaag.

Amsi 30 oktober 2020 09:18

Zullen met serieuze adelbrieven mogen komen om mijn vertrouwen te herwinnen.
Zal zeker niet de enigste zijn , succes allen.

6.454 Posts, Pagina: « 1 2 3 4 5 6 ... 179 180 181 182 183 184 185 186 187 188 189 ... 319 320 321 322 323 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	22 sep 2023
Koers	0,290
Verschil	0,000 (0,00%)
Hoog	0,000
Laag	0,000
Volume	0
Volume gemiddeld	0
Volume gisteren	112.228

Biocartis nieuws

Meer ››